Toxic Epidermal Necrolysis in a Patient with Hepatocellular Carcinoma Receiving Pembrolizumab Plus Regorafenib: A Case Report
This case affirms that early recognition, a systematic protocol involving high-dose corticosteroids/intravenous immunoglobulin, and multidisciplinary collaboration are vital for managing life-threatening cutaneous irAEs, while also highlighting that robust pharmacovigilance and patient education are fundamental to the safe implementation of ICI-based combination therapies.
Authors
- Siting Deng
- Li Ye (ORCID: https://orcid.org/0000-0001-7048-6024)
- Sijie Liu
- Xuehong Zhou
- Xueli Zhao
- Xiaoshi Zhu
Institutions
- University of Electronic Science and Technology of China (CN)
- People’s Hospital of Wenshan Prefecture (CN)
- Fourth People's Hospital of Sichuan Province (CN)
- Maternal and Child Health Hospital of Sichuan Province (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/cmar.s578836
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 32.57